Worry less about the small number of proposals that might appeal, which are just processes, and focus on those that risk ravaging pricing and decision-making in a way that could ultimately impact patients negatively.
What matters now is avoiding delusion and not repeating previous mistakes
February 7, 2024 Latest NewsBioPharmaComment![](https://e76bb9fd1f54a7a912eb-40f6ec802f763655ee14c32dfe77820e.ssl.cf4.rackcdn.com/48128061eb600c58f337f72ba5f87c8f.png)
Latest Video
New Stories
-
The 'Week in Review' - 24 January
January 24, 2025 - - Podcast -
Cabinet documents reveal decades-old focus on faster PBS listings
January 24, 2025 - - Latest News -
No probity advisor but what about a form of confidentiality deed?
January 24, 2025 - - Latest News -
CEPI backing for Vaxxas to advance needle-free thermostable mRNA vaccines
January 23, 2025 - - Latest News -
New preventive treatments could support ongoing fight against COVID
January 23, 2025 - - Latest News -
Pharmac encourages input on on multiple medicines funding proposal
January 22, 2025 - - Latest News -
Immutep completes patient enrolment for EFTISARC-NEO Phase 2 trial
January 22, 2025 - - Australian Biotech